l e t t e r s
Analysis of abnormally methylated genes is increasingly important in basic research and in the development of cancer biomarkers 1,2 . We have developed methyl-BEAMing technology to enable absolute quantification of the number of methylated molecules in a sample. Individual DNA fragments are amplified and analyzed either by flow cytometry 3 or next-generation sequencing. We demonstrate enumeration of as few as one methylated molecule in ~5,000 unmethylated molecules in DNA from plasma or fecal samples. Using methylated vimentin as a biomarker in plasma samples, methyl-BEAMing detected 59% of cancer cases. In early-stage colorectal cancers, this sensitivity was four times more than that obtained by assaying serum-carcinoembryonic antigen (CEA). With stool samples, methyl-BEAMing detected 41% of cancers and 45% of advanced adenomas. In addition to diagnostic and prognostic applications, this digital quantification of rare methylation events should be applicable to preclinical assessment of new epigenetic biomarkers and quantitative analyses in epigenetic research.
In humans, DNA methylation is largely restricted to cytosines within 5′-CpG dinucleotides. This covalent modification of DNA functions as an important mediator of gene regulation and, together with covalent modifications of histone proteins, forms the cornerstone for the burgeoning field of epigenetics. Cancer cells are characterized by hypomethylation throughout their genomes 4 plus hypermethylation of specific regions, that in certain genes has been associated with transcriptional silencing 5 .
Analysis of DNA methylation is leading to a new generation of cancer biomarkers 6 . Although certain genomic mutations provide exquisitely specific biomarkers 7, 8 , their utility is compromised by their heterogeneity: the same gene can be mutationally inactivated through many different mechanisms or mutated at many different positions. In contrast, DNA hypermethylation in cancers often affects identical residues in the regulatory regions of particular genes, providing major advantages when designing biomarker assays. Accordingly, many studies have employed DNA methylation of specific genes for diagnostics development 2, 5, 6, 9 . Such diagnostic tests can in principle be used for early detection of cancers, for assessing prognosis, and for determining the effects of therapy or detecting residual disease.
The majority of diagnostic tests based on DNA methylation have employed bisulfite to convert cytosine residues to uracils. This conversion alters the sequence of DNA 10 , providing an opportunity to assess DNA methylation with allele-specific PCR, restriction digestion or specific hybridization probes [11] [12] [13] [14] [15] . However, in many important diagnostic scenarios, DNA from the cancer represents only a small fraction of the total DNA in the clinical sample. Such scenarios include early diagnosis or therapeutic monitoring, for which DNA from plasma, serum, urine, feces or sputum is used, and monitoring the extent of disease, for which DNA from surgical margins or lymph nodes is used 1 .
Digital approaches involve the counting of methylated and unmethylated fragments, one-by-one, thereby dramatically increasing the signalto-noise ratio of the assay. A digital method 16 for DNA methylation analysis would have several advantages, such as enabling increased sensitivity for disease detection, increased test specificity and enabling comparisons across different patient cohorts for standardized clinical interpretations. However, no such methods are currently available for detecting cancer-associated methylation at specific sites in samples from cancer patients. Methyl-BEAMing technology, which extends the digital BEAMing 3 (beads, emulsion, amplification and magnetics) technology to analysis of DNA methylation, addresses this need.
DNA in clinical samples such as plasma has already been degraded to small fragments by nucleases and is present at only a few nanograms per mililiter 7 . Conventional methods for bisulfite conversion further degrade DNA and are difficult to implement with samples containing only small amounts of DNA because of cumulative losses during the procedure 17, 18 . After much optimization to maximize the sensitive digital quantification of DNA methylation in clinical samples l e t t e r s extent of bisulfite conversion while minimizing bisulfite-associated DNA fragmentation, we identified conditions that resulted in nearly complete (99.4%; 95% CI, 98.6-99.8%) conversion of deoxycytosine to deoxyuracil residues while preserving the majority of the DNA.
Exon 1 of the vimentin gene is hypermethylated in colorectal cancers when compared to healthy colorectal mucosae and other healthy tissues 19, 20 . This difference is the basis for the only commercially available diagnostic test based on DNA methylation (ColoSure, LabCorp). To assess the dynamic range and accuracy of methyl-BEAMing, we designed primers to amplify ~100 bp of the vimentin gene exon 1 that contains the 5′ CpG sites known to be methylated in cancer cells.
Amplicons of ~100 bp were chosen to accommodate the small size of circulating DNA molecules 7, 21 . The PCR primers were designed to amplify bisulfite-converted products derived from both methylated and unmethylated vimentin templates. The methylation status of these amplicons was then digitally enumerated by BEAMing 3 .
In BEAMing 3 , PCR amplification of individual DNA molecules takes place within aqueous nanocompartments suspended in a continuous oil phase ( Fig. 1a and Supplementary Fig. 1 ). Each aqueous nanocompartment contains the DNA polymerase, cofactors and dNTPs required for PCR. When a compartment contains a single DNA template molecule as well as a bead, the PCR product within the l e t t e r s compartment becomes bound to the bead. Each bead thereby ends up with thousands of identical copies of the template within its nanocompartment-a process similar to that resulting from cloning an individual DNA fragment into a plasmid vector to form a bacterial colony. After PCR, the beads are collected by breaking the emulsion, and their status is individually assessed by incubation with fluorescent hybridization probes. In methyl-BEAMing, the status of harvested beads is interrogated by fluorescent probes that specifically hybridize to bisulfite-converted sequences derived from either methylated or unmethylated parental DNA sequences. Flow cytometry then provides an accurate enumeration of the original template molecules that are methylated or unmethylated within the queried sequence (Fig. 1b) .
We first tested methyl-BEAMing on mixtures of DNA derived from peripheral blood lymphocytes (unmethylated vimentin) and a colorectal cancer cell line (fully methylated vimentin). We found that the fraction of beads containing methylated vimentin sequences was directly proportional to the fraction of methylated input DNA (R 2 = 0.99, Supplementary Fig. 2 ). Moreover, methyl-BEAMing could accurately detect methylated vimentin DNA in a mixture that contained only a single DNA molecule of methylated vimentin exon 1 sequences mixed with 1,000 copies of unmethylated vimentin exon 1 sequences (that is, detection of 0.1% of methylation target). In contrast, in parallel assays, a previously optimized methylationspecific PCR assay did not detect methylated templates when the fraction of methylated fragments was <6.2% (Supplementary Table 1) . Methyl-BEAMing thus enabled accurate detection of a single copy of methylated vimentin sequences in a mixture and enhanced overall technical sensitivity for detecting methylated vimentin exon 1 DNA by at least 62-fold relative to methylation-specific PCR.
Cancer biomarkers, particularly circulating molecules, can be useful for early detection or monitoring of disease after therapy. The ability to detect and count a single molecule of methylated DNA suggested that methyl-BEAMing could be applied for such purposes. To determine the sensitivity and specificity of methylBEAMing in plasma samples, we evaluated 191 samples, 81 from patients with colorectal cancer and 110 from age-and sex-matched controls. The total amount of DNA in the plasma was somewhat higher in patients with cancer than in the cancerfree controls, as expected 2 ( Supplementary  Fig. 3 ). The average fraction of methylated vimentin fragments was very low in the healthy controls (mean value of l e t t e r s 0.026%); the fraction was larger in each successive cancer stage, increasing monotonically from cases confined to the wall of the colon (Duke's A and B), to cases with spread to local lymph nodes (Duke's C), and reaching a mean of 4.4% in cases with metastasis to distant organs (Duke's D; Table 1 ). The theoretical limit of detection in any digital assay is one event; in the current study, the limit of detection was one methylated vimentin fragment in the 2 ml plasma that was assayed for each patient. Using this cutoff, the sensitivity of methyl-BEAMing was 59% (95% CI, 48-70%) in cancer patients (where sensitivity is the fraction of all disease cases detected). The specificity was 93% (95% CI, 86-97%) (where [1 -specificity] is the percent of all healthy persons testing positive); 8 of the 110 healthy samples contained ≥1 methylated vimentin fragment per 2 ml plasma; Fig. 2b) . Importantly, the sensitivity for detecting colorectal cancer was 52% (95% CI, 37-68%, 23 of 44 cases) in the individuals with Duke's A and B cancers, most of whom were likely to be cured by conventional surgery (P = 3 × 10 −9 for distinguishing individuals with Duke's A-and B-stage cancers from those cancerfree; Table 1 and Fig. 2a,b) . Serum CEA is the only colorectal cancer biomarker in current used clinically, most often for early detection of colorectal cancer recurrence. For 43 of those with Duke's A-and B-stage cases, preoperative serum CEA values had also been determined. Only 6 of them (14%, 95% CI, 5-28%) had serum CEA values exceeding the standard clinical upper limit of cancer-free populations (5 ng/ml). Thus, methyl-BEAMing provided a significant increase in the ability to detect curable early-stage colorectal cancers by assaying blood (52% versus 14%, P = 2 × 10 −4 ; Supplementary Fig. 4 ).
Serum CEA values were also available for 74 members of our healthy control cohort, of whom 7 had values >5 ng/ml, corresponding to a CEA specificity of 91% (95% CI, 81-96%). The area under the receiver operating characteristic (ROC) curve for methyl-BEAMing was 0.81 (varying from 0.67 to 0.95 among the four cancer stages), whereas the corresponding value for CEA was 0.63 (varying from 0.42 to 0.97; Fig. 2c,d ).
Values for circulating methylated vimentin fragments and CEA were additionally determined from matched pre-and post-surgical blood samples of three colon cancer patients (Supplementary Table 3) . Patient 1 had recurrent metastatic disease in the liver. The CEA was approximately twice the upper limit for healthy individuals, whereas circulating methylated vimentin DNA was >100-fold above the healthy threshold. The patient underwent resection of his liver metastasis but was later found to have a residual solitary lung metastasis. A month after surgery, CEA levels had returned to normal and levels of methylated vimentin DNA in the circulation had decreased 20-fold. However, an abnormal level of methylated vimentin DNA continued to be detectable (7.2 molecules per 2 ml plasma), consistent with this person's residual disease.
Patient 2 had recurrent metastatic disease in the liver, with CEA levels elevated 1.5-fold and levels of circulating methylated vimentin DNA elevated 800-fold over the upper limit for healthy individuals. One month after liver resection and radio-frequency ablation, the CEA level returned to normal. Methylated vimentin levels fell 2.5-fold but were still elevated (320 molecules per 2 ml of plasma). One month after these results, positron emission and computed tomography (PET and CT) imaging confirmed the presence of remaining active metastatic disease in both the lung and the liver.
Patient 3 had a cancer in the sigmoid colon and synchronous metastatic disease in the liver. The CEA was within the range for healthy individuals, but circulating methylated vimentin DNA was elevated >440-fold. The patient underwent resection of his primary colon cancer and partial resection of his liver metastasis, and was started on chemotherapy for palliation of his residual disease. Measurement of circulating methylated vimentin DNA showed that its levels had fallen 440-fold, but still remained detectable, consistent with this patient's residual disease.
The near-disappearance of circulating methylated vimentin DNA after these surgeries suggests that these circulating methylated DNAs were derived directly from the malignant tumors. To further support this interpretation, we examined the plasma of two colorectal cancer patients and compared the fraction of methylated vimentin molecules (determined by methyl-BEAMing) versus the fraction of mutant molecules (APC gene G4189T and PIK3CA gene G1624A) determined by standard BEAMing 22 . In these patients, the mutations were somatic and therefore exclusively derived from the patients' cancer cells. The fraction of methylated vimentin templates in the first sample was 13.6%, similar to the fraction of mutated APC (17.5%). In the second patient's plasma, methylated vimentin represented 3.5% of the total vimentin templates, whereas mutated PIK3CA represented 3.0% of the PIK3CA templates.
Next, we used vimentin methyl-BEAMing to screen stool samples (4 g) from 80 people, including 38 individuals without any colorectal tumors, 20 patients with clinically significant adenomas (defined as ≥1 cm diameter) and 22 colorectal cancer patients of various stages. The concentration of vimentin DNA fragments in stool varied widely (Supplementary Fig. 5 ). Although there were no consistent differences between the concentrations of total vimentin DNA fragments in the three patient groups, there was a marked difference in the fraction of methylated fragments. This fraction increased from a mean of 0.96% in individuals without colorectal tumors to a mean of 3.8% and 7.3% in patients with adenomas and carcinomas, respectively ( Table  1 and Fig. 3a-c) . Using a threshold of 2% methylation, 45% (95% CI, 23-68%) and 41% (95% CI, 21-64%) of the patients with adenomas and carcinomas, respectively, scored positive in the methyl-BEAMing assay, whereas only 5% (95% CI, 0.6-18%) of the samples from individuals without cancer did so (P = 5.5 × 10 −4 and P = 1.1 × 10 −3 for the difference between normal individuals and those with adenomas and cancers, respectively) ( Table 1, Fig. 3a-c and Supplementary  Table 4) . In fecal DNA, methyl-BEAMing preserved sensitivity for cancer detection but markedly increased specificity compared to methylation-specific PCR-based detection of methylated vimentin sequences 20 . The corresponding areas under the ROC curves for methyl-BEAMing analysis of adenomas and carcinomas were 0.69 and 0.62, respectively (Fig. 3d) .
Sequencing-by-synthesis instruments provide an alternative way to digitally assess DNA methylation. The methods we developed for bisulfite conversion and recovery of DNA from clinical samples can also be applied to DNA prepared for such instruments. Although the cost and throughput of sequencing-by-synthesis limits the use of these instruments in the clinic, they provide a way to validate the accuracy of methyl-BEAMing. For this purpose, we evaluated five samples with low and high fractions of methylated fragments on an Illumina Genome Analyzer sequencing instrument. After bisulfite conversion and PCR amplification (Fig. 1a and Supplementary  Fig. 1) , the PCR products were ligated to adapters and sequenced using a standard Illumina protocol. The 36-base region sequenced l e t t e r s with the Illumina instrument encompassed the five core CpGs that were assessed with the hybridization probes used in methyl-BEAMing. Through the analysis of cytosine residues not present within CpG motifs from normal lymphocyte DNA, we found that the bisulfite conversion efficiency used for methyl-BEAMing was 99.4% (95% CI, 98.6-99.8%). In this sample, the fraction of sequenced fragments in which four or five of the five core CpG sites were methylated was 0.015%. Given the high efficiency of the bisulfite conversion step, this low level of background methylation across multiple CpG sites likely arises from a low but real level of vimentin exon 1 methylation in lymphocytes (P < 0.0001, binomial distribution). Analysis of this sample by methyl-BEAMing determined that the methylated DNA fraction was 0.018%. Thus, in a sample with an extremely low content of methylated DNA sequences, enumeration of methylated sequences by either next-generation sequencing or by methyl-BEAMing gave essentially the same result. Likewise, in a sample from fecal DNA with a high degree of methylation, the fraction of methylated fragments determined by either sequencing or methyl-BEAMing was similar (11.1% versus 10.8%, respectively; Supplementary Table 5 ). This was substantiated in three other samples, one with a low level of methylation and two with relatively high levels. These data demonstrate that methyl-BEAMing provides the same precision for enumerating methylated DNA molecules as does next-generation sequencing across a wide range of methylated DNA inputs, though at a fraction of the time and the cost.
Our results demonstrate that methyl-BEAMing enables digital quantification of DNA methylation in clinical samples. One of the most important applications of methyl-BEAMing is in early diagnosis. In this study, cancer was detected by a plasma-based methyl-BEAMing assay in 59% (95% CI, 48-70%) of patients with colorectal cancer. This sensitivity is close to the maximal detectable with the vimentin biomarker, which has been shown to be methylated in 53-83% of colorectal cancers 20 . The fact that 52% (95% CI, 37-68%) of presumably curable Duke's A-and B-stage cancers could be detected by this method, in a cohort in which only 14% (95% CI, 0.6-18%) of cancers could be detected by CEA, is particularly encouraging. Equally encouraging is the observation that 45% (95% CI, 23-68%) of patients with clinically significant premalignancies (advanced adenomas) could be detected by methyl-BEAMing of fecal DNA. Patients with these lesions would generally be treated by endoscopic excision without abdominal surgery. The 45% detection rate of advanced adenomas by methylBEAMing observed in this study exceeds the 25-27% detection rate reported for comparably specific immunochemical fecal occult blood tests (specificity 93-97%) 23 . In screening an asymptomatic cohort of adults over age 50, the prevalence of colorectal adenomas 1 cm or larger and of colorectal cancer is expected to be 6.0% and 0.5-1.0%, respectively 24, 25 . Detection of 45% (95% CI, 23-68%) of adenomas and 41% (95% CI, 21-64%) of colorectal cancers by methyl-BEAMing of stool DNA, at 95% (95% CI, 82-99.4%) specificity, would translate into a positive predictive value of 40% for an individual with a positive test harboring an advanced colorectal adenoma or cancer. This value exceeds that achieved in many studies of mammography, a cancer screening test of established clinical value in reducing mortality 26 . Moreover, methyl-BEAMing represents a flexible platform. Applying methyl-BEAMing to a panel of suitable markers would increase sensitivity for colorectal cancer detection even further. With identification of suitable markers, the technique could be applied for early detection of other malignancies. One could also imagine application of methyl-BEAMing to prenatal testing, for example for Down's syndrome, based on enumeration of circulating chromosome 21-derived sequences that are specifically methylated in the fetus.
METhoDs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. 
oNLINE METhoDs
Sample collection and DNA purification. Plasma samples were collected by study nurses of Indivumed, Hamburg, Germany, from surgery patients treated in hospitals of Indivumed's collaborative network, and in particular from patients at the Israelitic Hospital and Clinic Alten Eichen (both in Hamburg, Germany) following strictly controlled standard operating procedures criteria. Investigational Review Board approval was provided by the Ethical Board of the Physicians Association of Hamburg and patient samples and data were collected only after informed, written consent was obtained. The samples used in the current study were randomly chosen from those contributing through this protocol. Shortly before surgery, 18 ml of blood was taken from a central catheter and loaded into a standard blood collection tube containing EDTA. The tube was immediately chilled to 8 °C and transported to the laboratories within 30 min for plasma preparation. The blood cells were pelleted for 15 min at 200g in a Leucosep tube (Greiner) filled with 15 ml of Ficoll-Paque solution. After centrifugation, the supernatant (that is, plasma) was transferred into 1.5 ml tubes, immediately frozen, and stored at −80 °C. The plasma samples were thawed at 25 °C for 5 min, and any remaining debris was pelleted at 16,000g for 5 min. The supernatant was transferred to a new tube. Total genomic DNA was purified from the 2 ml plasma supernatant using the QIAamp MinElute Virus Vacuum Kit (Qiagen) as recommended by the manufacturer. The DNA was eluted in elution buffer (Qiagen), and stored at −20 °C.
Stool samples and clinical data were collected from patients undergoing colonoscopy at Aarhus University Hospital. The study was approved by the Regional Scientific Ethics Committee, Aarhus, Denmark and by the Danish Data Protection Agency and informed, written consent was obtained in every case. Stool samples were collected on a weekday before bowel preparation for colonoscopy or operation for colorectal cancer. The patients placed the container in an insulated box containing frozen bags which had been stored in a freezer for at least 24 h. The box was collected at the patient's home within 8 hours. Immediately after the stool sample arrived at Aarhus University Hospital, the container was frozen at −80 °C until it was thawed for DNA purification. Stool samples were homogenized with a stool shaker (Exact Sciences). After homogenization, a 4 g stool equivalent of each sample was subjected to 2 centrifugations (5 min at 2,536g and 10 min at 16,500g). The supernatant was incubated with 20 µl RNase (0.5 mg/ml) for 1 hour at 37 °C, followed by precipitation with 1/10 volume of sodium acetate (3 M) and an equal volume of isopropanol. Stool DNA was dissolved in 4 ml of TE buffer (10 mM Tris, pH 8, 1 mM ethylenediamenetetraacetic acid [EDTA] ) and prepared for electrophoretic capture by mixing with 4 ml of water, 1 ml of 10 × TBE (890 mM Tris base, 890 mM boric acid, 20 mM EDTA), and 1 ml of 10% SDS. DNA samples were denatured at 95 °C for 15 min and then cooled on ice for 15 min. Vimentin fragments were then purified using a reversible electrophoretic capture affinity protocol (RECAP) 27 . This was accomplished by repeatedly driving the DNA back and forth through the capture device loaded with oligonucleotide probes for the vimentin gene target (capture probe sequences were 5′-biotin-CGCCACCCTCCGCAGCCATGTCCACCAGGTCCG-3′ and 5′-biotin-GGCCATCGCCACCCTCCGCAGCCATGTCCACCAGG-3′). After completion of electrophoretic cycling, the capture device was moved to a wash plate and washed four times with 500 µl of ST buffer (150 mM NaCl, 15 mM Tris-HCl, pH 7.4). The captured human DNA was eluted by adding 100 µl of 0.1 M NaOH to the capture device. The eluate was then neutralized with 10 µl of neutralization buffer (60 mM Tris pH 9.0, 6 mM EDTA, 0.5 M HCl).
Real-time PCR. The amount of DNA per 2 ml plasma samples was quantified using a modified version of a human LINE-1 quantitative real-time PCR assay 28 . Two primer sets were designed to amplify differently sized regions within the most abundant consensus region of the human LINE-1 family (for the 91-bp product, the primers were 5′-TGGCACATATACACCATGG AA3′ and 5′-TGATGGTTTCCAATTTCATCC-3′; for the 69-bp product, the primers were: 5′-TGGCACATATACACCATGGAA-3′ and 5′-TGTCCC TACAAAGGATATGAACTC-3′). PCR was performed in 25 µl reaction volumes consisting of template DNA equivalent to 25 µl of plasma, 0.5 U of platinum Taq DNA polymerase (Invitrogen), 1 × PCR buffer (67 mM Tris-HCl (pH 8.8), 16.6 mM (NH 4 ) 2 SO 4 , 10 mM β-mercaptoethanol, 1.17 mM MgCl 2 ), 6% (vol/vol) DMSO, 1 mM of each dNTP, 1:100,000 dilution of SYBR Green I (Invitrogen), and 0.2 µM of each primer. Amplification was carried out in an iCycler
